美股期權個股詳情
INMB241220C25000
- 0.34
- 0.000.00%
延時15分鐘行情收盤價 11/26 16:00 (美東)
0.00最高價0.00最低價
0.34今開0.34昨收0張成交量164張未平倉合約數25.00行權價0.00成交額435.60%引伸波幅419.26%溢價2024/12/20到期日0.00内在价值100合約乘數23天距到期日0.34時間價值100合約規模美式期權類型0.1786Delta0.0484Gamma14.35槓桿倍數-0.0297Theta0.0003Rho2.56有效槓桿0.0032Vega
INmune Bio股票討論
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease
1 MINUTE AGO, 3:03 PM EDT
VIA GLOBENEWSWIRE
INMB
SHARE
Data from Animal Model Study Demonstrate XPro™ converts microglia from a demyelinating cell to a remyelinating cell
Multi-year study published has implications for many CNS diseases including Alzheimer's
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination
INmune Bio (NASDAQ: INMB) announces publication in Cell Reports demonstrating XPro™'s ability to promote remyelination in demyelinating disease animal models. The study, led by Dr. Leslie Probert at Hellenic Pasteur Institute, shows that XPro1595 converts microglia from damaging to reparative cells by blocking soluble TNF. This research has implications for treating various ...
• $SpringWorks Therapeutics (SWTX.US)$ +19.2% (Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase3DeFi Trial )
• $Roivant Sciences (ROIV.US)$ +7.1% (FDA has approved VTAMA (tapinarof) cream)
• $Ocugen (OCGN.US)$ +5.9% (announces that it is diversifying its innovative pipeline by introducing a Phase 3 cell therapy platform technology called Ne?Cart)
• $Champion Homes (SKY.US)$ +4.4% (In reaction to earnings）
• $網易 (NTES.US)$ +4.1% (In...
暫無評論